ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Quan Zheng
Matched on ORCID iD 0000-0002-4512-9233; OpenAlex author ID A5100750521. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 3 papers
Papers 7
- Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. First author DOI 10.1016/j.xpro.2025.103635↗
- Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. Co-author DOI 10.1016/j.ymthe.2025.09.004↗
- PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-3475↗
- Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Co-author DOI 10.1002/advs.202308990↗
- CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. First author DOI 10.1016/j.xcrm.2024.101692↗
- Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
- PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer Co-author DOI 10.1101/2021.11.15.468579↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Christopher Heeschen · 7 shared papers, 2021–2025 · strength 1.14
- Paper Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemore… DOI 10.1016/j.ymthe.2025.09.004↗
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3475↗
- Berina Šabanović · 5 shared papers, 2023–2025 · strength 0.87
- Paper Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemore… DOI 10.1016/j.ymthe.2025.09.004↗
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. DOI 10.1002/advs.202308990↗
- Chenlei Wen · 4 shared papers, 2024–2025 · strength 0.72
- Paper Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemore… DOI 10.1016/j.ymthe.2025.09.004↗
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. DOI 10.1002/advs.202308990↗
- Jiajia Tang · 4 shared papers, 2021–2025 · strength 0.57
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
- Paper Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. DOI 10.1186/s13046-023-02883-y↗
- Baiyong Shen · 3 shared papers, 2024–2025 · strength 0.55
- Paper Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemore… DOI 10.1016/j.ymthe.2025.09.004↗
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
- Da Fu · 3 shared papers, 2024–2025 · strength 0.50
- Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
- Paper Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. DOI 10.1002/advs.202308990↗
- Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
- Patricia Sancho · 3 shared papers, 2021–2025 · strength 0.42
- Paper PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3475↗
- Paper Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. DOI 10.1186/s13046-023-02883-y↗
- Paper PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer DOI 10.1101/2021.11.15.468579↗
- Bruno Sáinz · 3 shared papers, 2021–2025 · strength 0.42
- Paper PPARδ Orchestrates a Prometastatic Metabolic Response to Microenvironmental Cues in Pancreatic Cancer. DOI 10.1158/0008-5472.can-24-3475↗
- Paper Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. DOI 10.1186/s13046-023-02883-y↗
- Paper PPAR-delta acts as a metabolic master checkpoint for metastasis in pancreatic cancer DOI 10.1101/2021.11.15.468579↗
- Elisabetta Fenocchio · 2 shared papers, 2024–2025 · strength 0.33
- Yaru Zhao · 2 shared papers, 2024–2025 · strength 0.33
- Qi Wang · 2 shared papers, 2024–2025 · strength 0.33
- Petra Jagušt · 2 shared papers, 2021–2025 · strength 0.27
- Sarah Courtois · 2 shared papers, 2021–2025 · strength 0.27
- Sara Maria David Trabulo · 2 shared papers, 2021–2025 · strength 0.27
- Beatriz Parejo-Alonso · 2 shared papers, 2021–2025 · strength 0.27
- Pilar Espiau-Romera · 2 shared papers, 2021–2025 · strength 0.27
- Qian Yu · 1 shared paper, 2025 · strength 0.22
- Matthias M. Gaida · 1 shared paper, 2025 · strength 0.18
- Andrés Gordo-Ortiz · 1 shared paper, 2025 · strength 0.18
- Renfei Wu · 1 shared paper, 2024 · strength 0.17
- Jingwei Li · 1 shared paper, 2024 · strength 0.17
- Lingxi Jiang · 1 shared paper, 2024 · strength 0.17
- Baiyong Shen · 1 shared paper, 2024 · strength 0.17
- Ke Jiang · 1 shared paper, 2024 · strength 0.15
- Diana Behrens · 1 shared paper, 2023 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.